Triple therapy combination (mucolytic + PPI + dual antibiotics)

This page covers all Triple therapy combination (mucolytic + PPI + dual antibiotics) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Bacterial cell wall (penicillin-binding proteins) and bacterial ribosome (30S subunit), Glucocorticoid receptor (dexamethasone); bacterial 30S ribosome (tobramycin, netilimicin), DNA gyrase, 50S ribosomal subunit, penicillin-binding proteins.

Targets

Bacterial cell wall (penicillin-binding proteins) and bacterial ribosome (30S subunit) · Glucocorticoid receptor (dexamethasone); bacterial 30S ribosome (tobramycin, netilimicin) · DNA gyrase, 50S ribosomal subunit, penicillin-binding proteins · Bacterial cell wall (penicillin-binding proteins) and bacterial ribosome (50S subunit)

Marketed (3)

• N-acetylcysteine + PPI-amoxicillin-clarithromycin · National Taiwan University Hospital · Gastroenterology / Infectious Disease
  This combination therapy eradicates Helicobacter pylori infection by using antibiotics to kill the bacteria while N-acetylcysteine reduces mucus viscosity and a PPI suppresses gastric acid to optimize antibiotic efficacy.
• Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin · Centre Hospitalier Universitaire de Besancon · Infectious Disease
  This is a combination of multiple beta-lactam antibiotics and aminoglycosides that inhibit bacterial cell wall synthesis and protein synthesis to kill a broad spectrum of bacteria.
• Dexamethasone, tobramycin, netilimicin · Kasr El Aini Hospital · Ophthalmology / Otolaryngology / Infectious Disease
  This is a combination of a corticosteroid (dexamethasone) and two aminoglycoside antibiotics (tobramycin and netilimicin) that reduces inflammation and provides broad-spectrum bacterial coverage.

Phase 3 pipeline (2)

• levofloxacin, azithromycin, amoxicillin/clavulanate · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Infectious Diseases
  Levofloxacin, azithromycin, and amoxicillin/clavulanate inhibit bacterial growth through different mechanisms, targeting DNA gyrase, protein synthesis, and cell wall synthesis, respectively.
• Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin · Bayer · Infectious Disease
  This is a combination of four beta-lactam and macrolide antibiotics that work by inhibiting bacterial cell wall synthesis and protein synthesis to kill or inhibit growth of susceptible bacteria.

Patent intelligence

• antibiotics patent landscape — aggregated cliff calendar, attackable patents, originator estates